Kamebakaurine

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Kamebakaurin 能够保护肝脏免受 APAP 诱导的肝毒性，可能是通过抑制炎症反应和氧化应激来实现的。

Kamebakaurin has the ability to protect the liver from APAP-induced hepatotoxicity, presumably by both inhibiting the inflammatory response and oxidative stress. Kamebakaurin inhibits the expression of hypoxia-inducible factor-1α and its target genes to confer antitumor activity.Kamebakaurin has anti-cancer and anti-inflammatory activities through direct inhibition of DNA-binding activity of nuclear factor-kappa B (NF-κB) p50.Kamebakaurin has anti-neuroinflammatory activity via inhibition of c-Jun NH?-terminal kinase and p38 mitogen-activated protein kinase pathway in activated microglial cells.

——

——

——

MAPK/ERK Signaling

p38 MAPK

NF-κB

——

——

73981-34-7

350.45

C20H30O5

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (297.25 mM)

CC1(CCC(C2(C1CC(C34C2CCC(C3O)C(=C)C4=O)O)CO)O)C

Kaur-16-en-15-one, 1,7,14,20-tetrahydroxy-, (1alpha,7alpha,14R)-

(-20℃)

With Ice Pack

≥ 2 years